PMID- 31739840
OWN - NLM
STAT- MEDLINE
DCOM- 20200831
LR  - 20211204
IS  - 0031-7144 (Print)
IS  - 0031-7144 (Linking)
VI  - 74
IP  - 11
DP  - 2019 Nov 1
TI  - Efficacy of montelukast sodium chewable tablets combined with inhaled budesonide 
      in treating pediatric asthma and its effect on inflammatory factors.
PG  - 694-697
LID - 10.1691/ph.2019.9582 [doi]
AB  - The aim of this study was to explore the clinical effect of montelukast sodium 
      chewable tablets combined with inhaled budesonide in the treatment of pediatric 
      asthma and its influence on inflammatory factors. One hundred and thirty-five 
      asthmatic children were randomly divided into montelukast sodium group, 
      budesonide group and combined group. Clinical symptoms, lung function, 
      inflammatory factors and immune related indices of patients in each group were 
      observed and recorded. After treatment, the times to disappearance of wheezes, 
      dyspnea, asthma and hospital stay in the combined group were significantly 
      shorter than those in the single-drug group (all p < 0.001). Forced vital 
      capacity (FVC), forced expiratory volume in the first second (FEV1), peak 
      expiratory flow (PEF) were significantly higher than those before treatment, and 
      in the combined group value were significantly higher than in the single-drug 
      group in the same period (all p < 0.001). Tumor necrosis factor-alpha (TNF-alpha), 
      interleukin-4 (IL-4), IL-8 and hypersensitive C-reactive protein (hs-CRP) were 
      significantly lower than before treatment, and the combined group was 
      significantly lower than the single-drug group in the same period (all p < 0.05). 
      The number of CD4(+) and CD3(+) cells in the combined group was significantly 
      higher than that in the single-drug group, while the number of CD8 + cells and 
      the expression level of immune globulin E (IgE) were significantly lower (all p < 
      0.05). There was no difference in the incidence of adverse reactions between the 
      groups during treatment (p > 0.05). Six months after treatment, the incidence of 
      asthma in the combined group was significantly lower than that in the single-drug 
      group (both p < 0.05). Montelukast sodium chewable tablets combined with inhaled 
      budesonide can shorten the discomfort duration of asthmatic children and help 
      them restore lung function. Moreover, it reduces the level of inflammatory 
      factors and increases the resistance of children, which is worthy of further 
      promotion and application.
FAU - Zhang, Yu
AU  - Zhang Y
FAU - Wang, Hai
AU  - Wang H
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Pharmazie
JT  - Die Pharmazie
JID - 9800766
RN  - 0 (Acetates)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Cyclopropanes)
RN  - 0 (Glucocorticoids)
RN  - 0 (Quinolines)
RN  - 0 (Sulfides)
RN  - 0 (Tablets)
RN  - 51333-22-3 (Budesonide)
RN  - MHM278SD3E (montelukast)
SB  - IM
MH  - Acetates/*administration & dosage/adverse effects
MH  - Administration, Inhalation
MH  - Administration, Oral
MH  - Anti-Asthmatic Agents/*administration & dosage/adverse effects
MH  - Asthma/*drug therapy/physiopathology
MH  - Budesonide/*administration & dosage/adverse effects
MH  - Child
MH  - Child, Preschool
MH  - Cyclopropanes
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glucocorticoids/administration & dosage/adverse effects
MH  - Humans
MH  - Inflammation/drug therapy/physiopathology
MH  - Male
MH  - Quinolines/*administration & dosage/adverse effects
MH  - Respiratory Function Tests
MH  - Sulfides
MH  - Tablets
MH  - Treatment Outcome
EDAT- 2019/11/20 06:00
MHDA- 2020/09/01 06:00
CRDT- 2019/11/20 06:00
PHST- 2019/11/20 06:00 [entrez]
PHST- 2019/11/20 06:00 [pubmed]
PHST- 2020/09/01 06:00 [medline]
AID - 10.1691/ph.2019.9582 [doi]
PST - ppublish
SO  - Pharmazie. 2019 Nov 1;74(11):694-697. doi: 10.1691/ph.2019.9582.